Leukemia is a type of cancer that affects the blood. The two most common types in children are acute lymphoblastic leukemia and acute myelogenous leukemia.
In a person with leukemia, blood cells are released into the bloodstream before they are fully formed, so there are fewer healthy blood cells in the body.
Below, we describe the types of childhood leukemia, the symptoms, and the treatments. We then look at when to contact a doctor, what questions to ask, and where to find support.
Childhood leukemia is the most common form of cancer in children. It affects up to 3,800 children under the age of 15 in the United States each year.
Leukemia occurs when bone marrow releases new blood cells into the bloodstream before they are fully mature.
These immature blood cells do not function as they should, and eventually, the number of immature cells overtakes the number of healthy ones.
Leukemia can affect red and white blood cells and platelets.
The bone marrow produces stem cells. A blood stem cell can become a myeloid stem cell or a lymphoid stem cell.
Lymphoid stem cells become white blood cells. Myeloid stem cells can become:
Leukemia is typically acute or chronic, and chronic types are rare in children. They can include chronic myeloid leukemia or chronic lymphocytic leukemia.
Most childhood leukemias are acute, meaning that they progress quickly and need treatment as soon as possible.
Acute lymphoblastic leukemia (ALL) is the most common type in children, accounting for 75% of childhood leukemia cases.
It affects cells called lymphocytes, a type of white blood cell.
In a person with ALL, the bone marrow releases a large number of underdeveloped white blood cells called blast cells. As the number of these increases, the number of red blood cells and platelets decreases.
There are two subtypes of ALL: B-cell and T-cell.
In most childhood cases of ALL, the cancer develops in the early forms of B-cells. The other type, T-cell ALL, typically affects older children.
Research from 2020 reports that the majority of people diagnosed with ALL are under 18 and typically between 2 and 10 years old.
The American Cancer Society report that children under 5 years old have the highest risk of developing ALL and that this risk slowly declines until a person reaches their mid-20s.
The outlook for ALL depends on the subtype, the persons age, and factors specific to each person.
Myeloid leukemias account for approximately 20% of childhood leukemia cases, and most myeloid leukemias are acute.
Acute myelogenous leukemia (AML) affects white blood cells other than the lymphocytes. It may also affect red blood cells and platelets.
AML can begin in:
Juvenile myelomonocytic leukemia (JMML) accounts for approximately 12% of leukemia cases in children.
This rare type is neither acute nor chronic. JMML begins in the myeloid cells, and it typically affects children younger than 2 years.
Symptoms can include:
The symptoms of leukemia may be nonspecific similar to those of other common childhood illnesses.
A doctor will ask how long the child has been experiencing the symptoms, which can include:
Children may experience specific symptoms depending on the type of blood cell that the leukemia is affecting.
A low number of red blood cells can cause:
A low number of healthy white blood cells can cause infections or a fever with no other sign of an infection.
A low platelet count can cause:
Various factors can increase a childs risk of leukemia, and most are not preventable.
The following genetic conditions can increase the risk of leukemia:
Also, having a sibling with leukemia may increase the risk of developing it.
These can include exposure to:
If a child has symptoms that might indicate leukemia, a doctor may perform or request:
A bone marrow aspiration involves using a syringe to take a liquid sample of bone marrow cells. The doctor may give the child a drug that allows them to sleep through this test.
During the diagnostic process, a person might ask:
The doctor may recommend a variety of treatments for childhood leukemia, and the best option depends on a range of factors specific to each person.
The treatment usually consists of two phases. The first aims to kill the leukemia cells in the childs bone marrow, and the second aims to prevent the cancer from coming back.
The child may need:
Before or during treatment, a person might ask the doctor:
Questions to ask after the treatment might include:
Children who have undergone leukemia treatments require follow-up care, as the treatments often cause late effects.
These can develop in anyone who has received treatment for cancer, and they may not arise for months or years after the treatment has ended.
Treatments that can cause late effects include:
These complications may affect:
The late effects that may come can also depend on the type of treatment and the form of leukemia.
Because many leukemia symptoms can also indicate other issues, it can be hard to know when to contact a doctor.
Overall, it is best to seek medical advice if a child shows symptoms or behaviors that are not normal for them.
If a child has received a leukemia diagnosis, the effects can extend to parents, other family members, caregivers, and friends.
A person can find support and additional resources from:
The following organizations based in the United Kingdom also provide support and guidance:
Childhood leukemia can affect mental health, as well as physical health.
Learn more about mental health resources here.
According to the American Cancer Society, most children with leukemia have no known risk factors. There is no way to prevent leukemia from developing.
Because there are very few lifestyle-related or environmental causes of childhood leukemia, it is very unlikely that a caregiver can do anything to help prevent the disease.
A childs outlook depends on the type of leukemia. It is important to keep in mind that current estimates do not take into account recent advances in technology and medicine.
For example, the most recent 5-year survival rate estimates reflect the experiences of children who received their diagnoses and treatments more than 5 years ago.
The American Cancer Society report that the 5-year survival rate for children with ALL is 90%. The same rate for children with AML is 6570%.
Childhood leukemia is typically acute, which means that it develops quickly. As a result, a person should contact a doctor if they notice any of the symptoms.
The most common type of childhood leukemia is ALL, representing 3 out of 4 leukemia cases in children.
Treatment may include a combination of chemotherapy, targeted drugs, immunotherapy, stem cell transplants, surgery, and radiation.
The prognosis depends on the type of leukemia and the childs age.
This diagnosis can affect mental as well as physical health, and the effects can extend to caregivers, family members, and friends. Many different resources are available for support.
More:
Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020
- Cord Blood Banking Market Technological Innovations And Future Opportunities 202 - Fractovia News - November 7th, 2020